ServiziMenu principale

<< Torna a "Tutti gli studi"

C4221016 - A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Metastatic OR Unresectable Locally Advanced Melanoma (STARBOARD)

Studio Clinico

Patologia: Melanoma

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Multicentrico


Fase di studio: III

Richiesta mandatoria di tessuto: 

Linee di trattamento: Non applicabile

Criteri di inclusione: 

- Male or female participants ≥ 18 years at the time of informed consent.
- Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition.
- Presence of at least 1 measurable lesion as detected by radiological and/or photographic methods according to RECIST v1.1.
- ECOG performance status 0 or 1.
- Documented evidence of a BRAF V600E or V600K mutation in melanoma tumor tissue as previously determined by either PCR or NGS-based local laboratory assay (eg, US FDA-approved test, CE-marked [European conformity] in vitro diagnostic in EU countries, or equivalent), obtained during the course of normal clinical care, in a CLIA- or similarly certified laboratory.
- Submission of adequate tumor tissue (archival or newly obtained; block or slides to the sponsor central laboratory(ies) during the screening period and prior to enrollment (SLI)/randomization (Phase 3).
- Have not received prior first-line systemic therapy for metastatic or unresectable locally advanced melanoma.
- Adequate bone marrow function, hepatic and renal function.
- Capable of giving signed informed consent.

Criteri di esclusione: 

- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Mucosal or ocular melanoma.
- Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
- Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
- Unable to swallow, retain, and absorb oral medications.
- Impairment of GI function or disease which may significantly alter the absorption of oral study intervention (eg, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, including malabsorption syndrome secondary to prior GI surgery).
- Clinically significant cardiovascular diseases.
- History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to enrollment (SLI)/randomization (Phase 3). Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (ie, massive or sub-massive) deep vein thrombosis or pulmonary emboli.
- History or current evidence of RVO or current risk factors for RVO (eg, uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes); history of retinal degenerative disease.
- Concurrent neuromuscular disorder that is associated with the potential of elevated CK (eg, inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
- Current noninfectious pneumonitis or history of noninfectious pneumonitis requiring steroids.
- Evidence of HBV or HCV infection.
- Known history of a positive test for HIV or known AIDS.
- Any active infection requiring systemic therapeutic treatment within 2 weeks prior to enrollment (SLI)/ randomization (Phase 3).
- Participants with prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases.
- Concurrent or previous other malignancy within 2 years of study entry, except curatively treated basal or squamous cell skin cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, Bowen's disease and Gleason ≤ 6 prostate cancer. - Participants with a history of other curatively treated cancers must be reviewed with the sponsor or designee prior to entering the study.
- Participants who previously received and subsequently discontinued encorafenib and/or binimetinib and/or anti-PD-1/-L1 due to severe toxicity.
- For participants in the SLI only: Current use or anticipated need for food or drugs that are known moderate or strong CYP3A4 inhibitors during screening and through the DLT-evaluation period
- Participant has not recovered to Grade ≤ 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before enrollment (SLI)/ randomization (Phase 3).
- Receipt of protocol defined medications or treatments outside of required intervals before enrollment (SLI)/randomization (Phase 3):
- Previous administration with an investigational drug ≤ 6 months prior to enrollment (SLI)/randomization (Phase 3).
- Known sensitivity or contraindication to any component of study intervention (encorafenib, binimetinib and pembrolizumab), or their excipients.
- Pregnant, confirmed by a positive β-hCG laboratory test result, or is breastfeeding (lactating).
- Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members. 

Numero di pazienti previsti: 

77 (In Italia)

Schema di trattamento: 

Triplet Arm
Encorafenib and Binimetinib in combination with Pembrolizumab
Control Arm

Trattamento sperimentale: 

Encorafenib and Binimetinib in combination with Pembrolizumab

Trattamento di controllo: 


Obiettivi primari dello studio: 

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that:
1) is advanced or metastatic (spread to other parts of the body);
2) has a certain type of abnormal gene called 'BRAF'; and
3) has not received prior treatment.

Data di inizio dell'arruolamento: 11.02.2021

Data di fine dell'arruolamento: 29.01.2024

Centri partecipanti

Nord Italia

IRCCS A.O.U. San Martino - IST
Largo Rosanna Benzi 10 - 16132 Genova - GE

Riferimento: Dr. Francesco Spagnolo
Telefono: 0105558901


IRCCS Istituto Nazionale dei Tumori
Via Venezian 1 - 20133 Milano - MI


Istituto Europeo di Oncologia
Via Ripamonti 435 - 20141 Milano - MI

Riferimento: Dr.ssa Paola Queirolo
Telefono: 0257489459


Istituto Oncologico Veneto IRCCS
Via Gattamelata 64 - 35128 Padova - PD

Telefono: 3401981329


IRCCS Candiolo (TO)
St.Provinciale Km 3,95 SP142 - 10060 Candiolo - TO


Azienda Ospedaliera Santa Maria della Misericordia
Piazzale Santa Maria della Misericordia 15 - 33100 Udine - UD

Riferimento: Dr. Alessandro Minisini
Telefono: 0432552751


Centro Italia

Azienda Ospedaliera di Perugia
Via Dottori 1 - 06132 Perugia - PG
Ospedale Santa Maria della Misericordia

Riferimento: Prof. Mario Mandalà
Telefono: 0755784188


Istituto Dermopatico dell'Immacolata
Via Monti di Creta 104 - 00167 Roma - RM

Riferimento: Dr.ssa Federica De Galitiis
Telefono: 0666463393


Istituto Nazionale Tumori “Regina Elena”
Via Elio Chianesi 53 - 00144 Roma - RM
Oncologia Medica 1


Azienda Ospedaliera Universitaria Senese
Viale Bracci 16 - 53100 Siena - SI
AOUS Policlinico Le Scotte - UOC Immunoterapia Oncologica


Sud Italia e isole

Istituto Tumori “Giovanni Paolo II” IRCCS
Viale Orazio Flacco 65 - 70124 Bari - BA

Riferimento: Dr. Michele Guida
Telefono: 0805555136


Istituto Nazionale Tumori IRCCS Fondazione Pascale
Via Mariano Semmola - 80131 Napoli - NA
SC Oncologia Medica Melanoma Immunoterapia Oncologica e Terapie Innovative

Riferimento: Dr.ssa Ester Simeone
Telefono: 08117770387

Informazioni Generali


Numero di iscrizione a registro: 2020-004850-31

Data di inserimento: 25.02.2022

Data di aggiornamento: 03.11.2023





Principal Investigator ITALIA

Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale' - Napoli

Riferimento: Dr.ssa Ester Simeone

Telefono: 08117770387


Localita: Napoli


<< Torna a "Tutti gli studi"